Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 1/20 | 0.39 |
| ▸ | PPM1A | P35813 | 1/20 | 0.36 |
| ▸ | MPO | P05164 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 2/20 | 0.34 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 3/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13966273 | 0.91 | HTR4 (0.36) | HTR4MPOATMMAPTBTK | |
| SCHEMBL13966260 | 0.91 | HTR4 (0.47) | HTR4MPOATMMAPTTSHR | |
| SCHEMBL13966261 | 0.89 | MAPT (0.47) | HTR4ATMMAPTTSHRL3MBTL1 | |
| SCHEMBL13966272 | 0.89 | TRPA1 (0.44) | PPM1AATMMAPT | |
| SCHEMBL13966277 | 0.85 | TRPV4 (0.39) | PPM1ACYP1A2CYP2C9MAPK1 | |
| SCHEMBL13966377 | 0.85 | KIF11 (0.38) | HTR4PPM1AMPOATMMAPT | |
| SCHEMBL13966275 | 0.85 | HTR4 (0.36) | HTR4MPOATMMAPTBTK | |
| SCHEMBL13966264 | 0.83 | MAPT (0.47) | HTR4ATMMAPTTSHRL3MBTL1 | |
| SCHEMBL13966266 | 0.83 | MAPT (0.43) | ATMMAPT | |
| SCHEMBL13975767 | 0.81 | HTR4 (0.41) | HTR4MPOACHECYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8951964-B2 | Phenanthridine macrocyclic hepatitis C serine protease inhibitors | ABBVIE INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20120295842-A1 | PHENANTHRIDINE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ABBVIE INC. | 2012-11-22 | — | — | US | disclosed |
| US-20120295842-A1 | PHENANTHRIDINE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ABBVIE INC. | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295842-A1 | PHENANTHRIDINE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | TMPRSS15, HPN, PRSS1 | HTR4 2316/4885PPM1A 3025/4885MPO 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.